Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Le Monnier, A.
Duburcq, A.
Zahar, J.-R.
Corvec, S.
Guillard, T.
Cattoir, V.
Woerther, P.-L.
Fihman, V.
Lalande, V.
Jacquier, H.
Mizrahi, A.
Farfour, E.
Morand, P.
Marcadé, G.
Coulomb, S.
Torreton, E.
Fagnani, F.
and
Barbut, F.
2015.
Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
Journal of Hospital Infection,
Vol. 91,
Issue. 2,
p.
117.
Kwon, Jennie H.
Olsen, Margaret A.
and
Dubberke, Erik R.
2015.
The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection.
Infectious Disease Clinics of North America,
Vol. 29,
Issue. 1,
p.
123.
Heimann, S. M.
Vehreschild, J. J.
Cornely, O. A.
Wisplinghoff, H.
Hallek, M.
Goldbrunner, R.
Böttiger, B. W.
Goeser, T.
Hölscher, A.
Baldus, S.
Müller, F.
Jazmati, N.
Wingen, S.
Franke, B.
and
Vehreschild, M. J. G. T.
2015.
Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.
Infection,
Vol. 43,
Issue. 6,
p.
707.
McFarland, Lynne Vernice
Ozen, Metehan
Dinleyici, Ener Cagri
and
Goh, Shan
2016.
Comparison of pediatric and adult antibiotic-associated diarrhea andClostridium difficileinfections.
World Journal of Gastroenterology,
Vol. 22,
Issue. 11,
p.
3078.
Zhang, Shanshan
Palazuelos-Munoz, Sarah
Balsells, Evelyn M.
Nair, Harish
Chit, Ayman
and
Kyaw, Moe H.
2016.
Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study.
BMC Infectious Diseases,
Vol. 16,
Issue. 1,
Chopra, Teena
Goldstein, Ellie J.C.
and
Gorbach, Sherwood L.
2016.
Rethinking Strategies to Select Antibiotic Therapy inClostridium difficileinfection.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 36,
Issue. 12,
p.
1281.
Dieterle, Michael G.
and
Young, Vincent B.
2017.
Reducing Recurrence of C. difficile Infection.
Cell,
Vol. 169,
Issue. 3,
p.
375.
Reveles, Kelly R.
Backo, Jennifer L.
Corvino, Frank A.
Zivkovic, Marko
and
Broderick, Kelly C.
2017.
Fidaxomicin versus Vancomycin as a First‐Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 37,
Issue. 12,
p.
1489.
Zilberberg, Marya D.
Shorr, Andrew F.
Jesdale, William M.
Tjia, Jennifer
and
Lapane, Kate
2017.
Recurrent Clostridium difficile infection among Medicare patients in nursing homes.
Medicine,
Vol. 96,
Issue. 10,
p.
e6231.
Pak, Theodore R.
Chacko, Kieran I.
O’Donnell, Timothy
Huprikar, Shirish S.
van Bakel, Harm
Kasarskis, Andrew
and
Scott, Erick R.
2017.
Estimating Local Costs Associated WithClostridium difficileInfection Using Machine Learning and Electronic Medical Records.
Infection Control & Hospital Epidemiology,
Vol. 38,
Issue. 12,
p.
1478.
Couture-Cossette, Antoine
Carignan, Alex
Ilangumaran, Subburaj
and
Valiquette, Louis
2017.
Bezlotoxumab for the prevention ofClostridium difficilerecurrence.
Expert Opinion on Biological Therapy,
p.
1.
McFarland, Lynne V.
2017.
Primary prevention of Clostridium difficile infections – how difficult can it be?.
Expert Review of Gastroenterology & Hepatology,
Vol. 11,
Issue. 6,
p.
507.
Wilcox, Mark H.
Ahir, Harblas
Coia, John E.
Dodgson, Andrew
Hopkins, Susan
Llewelyn, Martin J.
Settle, Chris
Mclain-Smith, Susan
and
Marcella, Stephen W.
2017.
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Journal of Antimicrobial Chemotherapy,
Vol. 72,
Issue. 9,
p.
2647.
Basu, Anirban
Prabhu, Vimalanand S
Dorr, Mary Beth
Golan, Yoav
Dubberke, Erik R
Cornely, Oliver A
Heimann, Sebastian M
Pedley, Alison
Xu, Ruifeng
Hanson, Mary E
and
Marcella, Stephen
2018.
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Open Forum Infectious Diseases,
Vol. 5,
Issue. 11,
Dubberke, Erik R
Lee, Christine H
Orenstein, Robert
Khanna, Sahil
Hecht, Gail
and
Gerding, Dale N
2018.
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
Clinical Infectious Diseases,
Vol. 67,
Issue. 8,
p.
1198.
Zhang, Dongmu
Prabhu, Vimalanand S
and
Marcella, Stephen W
2018.
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Clinical Infectious Diseases,
Vol. 66,
Issue. 9,
p.
1326.
Tresman, Rebecca
and
Goldenberg, Simon D
2018.
Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.
Journal of Antimicrobial Chemotherapy,
Vol. 73,
Issue. 10,
p.
2851.
Ford, Diana C.
Schroeder, Mary C.
Ince, Dilek
and
Ernst, Erika J.
2018.
Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients.
American Journal of Health-System Pharmacy,
Vol. 75,
Issue. 15,
p.
1110.
Zilberberg, Marya D.
Nathanson, Brian H.
Marcella, Stephen
Hawkshead, John Jay
and
Shorr, Andrew F.
2018.
Hospital readmission with Clostridium difficile infection as a secondary diagnosis is associated with worsened outcomes and greater revenue loss relative to principal diagnosis.
Medicine,
Vol. 97,
Issue. 36,
p.
e12212.
Prabhu, Vimalanand S
Dubberke, Erik R
Dorr, Mary Beth
Elbasha, Elamin
Cossrow, Nicole
Jiang, Yiling
and
Marcella, Stephen
2018.
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Clinical Infectious Diseases,
Vol. 66,
Issue. 3,
p.
355.